Where are we heading to in pharmacological IBD therapy?
Zürich, Switzerland. In Pharmacol Res, Oct 2015
Some initially promising therapies will need further development or have failed such as Trichuris suis ova therapy (but not helminth therapy in general), CCR9 targeted therapies or recombinant IL-10.
Next-Generation Therapeutics for IBD.
Amsterdam, Netherlands. In Curr Gastroenterol Rep, Jun 2015
Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.